EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review

Lili Wang, Xinyang Chen, Yuanyuan Li, Hua Chang, Xiangkai Meng iD

The Oncologist · 08.05.2026 · 31 (6)

DOI: 10.1093/oncolo/oyag164 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Oncologist, online erschienen am 28.04.2026. Verfasst von Lili Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, the First Affiliated Hospital of China Medical University, Shenyang, 110001, China. Hauptthemen laut MEDLINE: Adenocarcinoma, Clear Cell, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy, Ovarian Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Ovarian clear cell carcinoma (OCCC) frequently exhibits resistance to conventional chemotherapy with limited treatment options. This study reports a heavily pretreated advanced case with liver metastases to investigate the efficacy of gemcitabine combined with PD-1 inhibitor in such refractory patients.

Methods

We present a case of stage IIIC OCCC that progressed after first-line platinum-based chemotherapy. The patient was treated with gemcitabine in combination with the PD-1 inhibitor toripalimab. Genetic alterations were analyzed using next-generation sequencing, and PD-L1 expression was assessed by immunohistochemistry (combined positive score [CPS]). Treatment response and safety profiles were regularly monitored.

Results

The combination therapy induced a complete remission lasting over 24 months, with a manageable safety profile. Molecular profiling revealed a loss-of-function mutation in ARID1A, which may enhance tumor sensitivity to gemcitabine, while elevated PD-L1 expression (CPS = 30) may serve as a predictive biomarker for immunotherapy response in OCCC. Notably, the deep and durable clinical response observed suggests a potential synergistic effect between gemcitabine and immunotherapy, wherein ARID1A deficiency-induced chemosensitivity may prime the tumor microenvironment for enhanced immune checkpoint inhibition, offering a compelling rationale for this combination strategy in platinum-resistant OCCC.

Conclusion

This study proposes a promising therapeutic strategy for advanced OCCC and supports the clinical value of molecular profiling-guided treatment. Both ARID1A status and PD-L1 expression warrant further validation as potential biomarkers in prospective clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma, Clear CellAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyOvarian NeoplasmsFemaleHumansAntibodies, Monoclonal, HumanizedDeoxycytidineGemcitabineAdultDNA-Binding ProteinsTranscription Factors

Stichwörter der Autor:innen

ARID1APD-1 inhibitorgemcitabineovarian clear cell carcinomaprecision therapytoripalimab

Substanzen

Antibodies, Monoclonal, HumanizedARID1A protein, humanDeoxycytidineGemcitabinetoripalimabDNA-Binding ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Gynecology, the First Affiliated Hospital of China Medical University, Shenyang, 110001, China.

ORCID-Profile: Xiangkai Meng

Zitieren

APA

Wang, L., Chen, X., Li, Y., Chang, H., & Meng, X. (2026). Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag164

Vancouver

Wang L, Chen X, Li Y, Chang H, Meng X. Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag164

BibTeX
@article{Wang2026,
  author = {Wang, Lili and Chen, Xinyang and Li, Yuanyuan and Chang, Hua and Meng, Xiangkai},
  title = {Durable response to chemoimmunotherapy in a patient with refractory metastatic ovarian clear cell carcinoma: a case report and literature review},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {6},
  doi = {10.1093/oncolo/oyag164}
}
Kostenlos starten →